Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer

Sandjar Djalalov, Jaclyn Beca, Jeffrey S Hoch, Murray Krahn, Ming Sound Tsao, Jean Claude Cutz, Natasha B. Leighl

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Fingerprint

Dive into the research topics of 'Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences